<DOC>
	<DOCNO>NCT00630812</DOCNO>
	<brief_summary>The purpose study examine efficacy safety 26 week treatment inhale mannitol subject cystic fibrosis . Previous study demonstrate improvement lung function , mucociliary clearance , change physical property mucus , 24 hour sputum weight quality life . The result study investigate confirm finding addition examine effect antibiotic use chest infection . It hypothesise inhaled mannitol beneficial effect compare control treatment . An open label phase 26 week duration follow blind 26 week phase . During open label phase subject receive active treatment .</brief_summary>
	<brief_title>Long Term Administration Inhaled Mannitol Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Mannitol</mesh_term>
	<criteria>1 . Have give write informed consent participate study accordance local regulation 2 . Have confirm diagnosis cystic fibrosis ( positive sweat chloride value â‰¥ 60 mEq/L ) and/or genotype two identifiable mutation consistent CF , accompany one clinical feature consistent CF phenotype ) 3 . Be age &gt; 6 year old 4 . Have FEV1 &gt; 40 % &lt; 90 % predict 5 . Be able perform technique necessary measure lung function 1 . Investigators , site personnel directly affiliate study , immediate family . Immediate family define spouse , parent , child sibling , whether biologically legally adopt . 2 . Be consider `` terminally ill '' eligible lung transplantation 3 . Have lung transplant 4 . Be use nebulized hypertonic saline 4 week prior visit 1 5 . Have significant episode hemoptysis ( &gt; 60 mL ) three month prior enrolment 6 . Have myocardial infarction three month prior enrolment 7 . Have cerebral vascular accident three month prior enrolment 8 . Have major ocular surgery three month prior enrolment 9 . Have major abdominal , chest brain surgery three month prior enrolment 10 . Have know cerebral , aortic abdominal aneurysm 11 . Be breast feeding pregnant , plan become pregnant study 12 . Be use unreliable form contraception ( female subject risk pregnancy ) 13 . Be participate another investigative drug study , parallel , within 4 week visit 0 14 . Have know allergy mannitol 15 . Be use beta blocker 16 . Have uncontrolled hypertension systolic BP &gt; 190 / diastolic BP &gt; 100 17 . Have condition situation Investigator 's opinion may put subject significant risk , may confound result may interfere significantly patient 's participation study 18 . Be 'Mannitol Tolerance Test positive '</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>cystic fibrosis</keyword>
	<keyword>mannitol</keyword>
	<keyword>mucoactive</keyword>
</DOC>